CLARITHROMYCIN FOR ORAL SUSPENSION |
ASSAY/Procedure |
USP36–NF31
|
3018 |
26-Jul-2013 |
1-Aug-2013 |
USP38–NF33
|
First Supplement to USP37–NF32
|
Change the subsection head Buffer: to: Buffer A: AND After the Buffer A subsection: Add Buffer B: 0.067 M dibasic potassium phosphate AND Line 1 of Mobile phase: Change Methanol and Buffer to: Methanol and Buffer A… Read More
Change the subsection head Buffer: to: Buffer A: AND After the Buffer A subsection: Add Buffer B: 0.067 M dibasic potassium phosphate AND Line 1 of Mobile phase: Change Methanol and Buffer to: Methanol and Buffer A AND Line 4 of Sample stock solution: Change with the aid of 330 mL of Buffer, to a 1000-mL volumetric flask containing 50 mL of Buffer. to: with the aid of 330 mL of Buffer B, to a 1000-mL volumetric flask containing 50 mL of Buffer B.
|
CLARITHROMYCIN EXTENDED-RELEASE TABLETS |
PERFORMANCE TESTS/Dissolution <711>/Test 4 |
USP36–NF31
|
3019 |
26-Jul-2013 |
1-Aug-2013 |
USP38–NF33
|
First Supplement to USP37–NF32
|
Line 2 of Standard solution: Change and Medium (96:4). to: and Medium (4:96). |
DACARBAZINE FOR INJECTION |
USP Reference standards <11> |
USP36–NF31
|
3137 |
26-Jul-2013 |
1-Aug-2013 |
USP38–NF33
|
First Supplement to USP37–NF32
|
Line 3 of USP Dacarbazine Related Compound B RS: Change C4H3N5O 137.10 to: C4H3N5O · H2O 155.12 |
CRYOPRESERVED HUMAN FIBROBLAST-DERIVED DERMAL SUBSTITUTE |
Total collagen content |
USP36–NF31
|
3155 |
26-Jul-2013 |
1-Aug-2013 |
USP38–NF33
|
First Supplement to USP37–NF32
|
Line 7 of Collagen calibration standards: Change by adding 25 mL, 50 mL, 100 mL, and 200 mL, to: by adding 25 μL, 50 μL, 100 μL, and 200 μL, |
DIPHENHYDRAMINE HYDROCHLORIDE CAPSULES |
Assay |
USP36–NF31
|
3276 |
26-Jul-2013 |
1-Aug-2013 |
USP38–NF33
|
First Supplement to USP37–NF32
|
Line 2: Change Mobile phase, Standard preparation, System suitability solution, and Chromatographic system—Prepare as directed in the Assay under Diphenhydramine Hydrochloride.
to: Mobile phase—Prepare a solution of acetonitrile, water,… Read More
Line 2: Change Mobile phase, Standard preparation, System suitability solution, and Chromatographic system—Prepare as directed in the Assay under Diphenhydramine Hydrochloride.
to: Mobile phase—Prepare a solution of acetonitrile, water, and triethylamine (50:
50: 0.5), adjust with glacial acetic acid to a pH of 6.5, filter, and degas. Make adjustments if necessary (see System Suitability under Chromatography <621>
). Standard preparation—Dissolve an accurately weighed quantity of USP Diphenhydramine Hydrochloride RS in water to obtain a solution having a known concentration of about 0.5 mg per mL. AND After the Assay preparation subsection: Add System suitability solution—Dissolve about 5 mg of benzophenone in 5 mL of acetonitrile, dilute with water to 100 mL, and mix. Transfer 1.0 mL of this solution and 5 mg of diphenhydramine hydrochloride to a 10-mL volumetric flask, dilute with water to volume, and mix. Chromatographic system (see Chromatography <621>)—The liquid chromatograph is equipped with a 254-nm detector and a 4.6-mm × 25-cm column that contains packing L10. The flow rate is about 1 mL per minute. Chromatograph the System suitability solution, and record the peak responses as directed for Procedure; the resolution, R, between the benzophenone and diphenhydramine peaks is not less than 2.0. Chromatograph replicate injections of the Standard preparation, and record the peak responses as directed for Procedure; the relative standard deviation is not more than 2.0%, and the tailing factor for the diphenhydramine hydrochloride peak is not more than 2.0.
AND Line 1 of Procedure: Change Proceed as directed for Procedure in the Assay under Diphenhydramine Hydrochloride. to: Separately inject equal volumes, about 10 μL, of the Standard preparation and the Assay preparation into the chromatograph, record the chromatograms, and measure the responses for the major peaks.
|
DIPHENHYDRAMINE HYDROCHLORIDE INJECTION |
Assay |
USP36–NF31
|
3276 |
26-Jul-2013 |
1-Aug-2013 |
USP38–NF33
|
First Supplement to USP37–NF32
|
Line 2: Change Mobile phase, Standard preparation, System suitability solution, and Chromatographic system—Prepare as directed in the Assay under Diphenhydramine Hydrochloride.
to: Mobile phase—Prepare a solution of acetonitrile, water,… Read More
Line 2: Change Mobile phase, Standard preparation, System suitability solution, and Chromatographic system—Prepare as directed in the Assay under Diphenhydramine Hydrochloride.
to: Mobile phase—Prepare a solution of acetonitrile, water, and triethylamine (50:
50: 0.5), adjust with glacial acetic acid to a pH of 6.5, filter, and degas. Make adjustments if necessary (see System Suitability under Chromatography <621>). Standard preparation—Dissolve an accurately weighed quantity of USP Diphenhydramine Hydrochloride RS in water to obtain a solution having a known concentration of about 0.5 mg per mL. AND After the Assay preparation subsection: Add System suitability solution—Dissolve about 5 mg of benzophenone in 5 mL of acetonitrile, dilute with water to 100 mL, and mix. Transfer 1.0 mL of this solution and 5 mg of diphenhydramine hydrochloride to a 10-mL volumetric flask, dilute with water to volume, and mix. Chromatographic system (see Chromatography <621>)—The liquid chromatograph is equipped with a 254-nm detector and a 4.6-mm × 25-cm column that contains packing L10. The flow rate is about 1 mL per minute. Chromatograph the System suitability solution, and record the peak responses as directed for Procedure; the resolution, R, between the benzophenone and diphenhydramine peaks is not less than 2.0. Chromatograph replicate injections of the Standard preparation, and record the peak responses as directed for Procedure; the relative standard deviation is not more than 2.0%, and the tailing factor for the diphenhydramine hydrochloride peak is not more than 2.0.
AND Line 1 of Procedure: Change Proceed as directed for Procedure in the Assay under Diphenhydramine Hydrochloride. to: Separately inject equal volumes, about 10 μL, of the Standard preparation and the Assay preparation into the chromatograph, record the chromatograms, and measure the responses for the major peaks.
|
DIPHENHYDRAMINE HYDROCHLORIDE ORAL SOLUTION |
Assay |
USP36–NF31
|
3277 |
26-Jul-2013 |
1-Aug-2013 |
USP38–NF33
|
First Supplement to USP37–NF32
|
Line 2: Change Mobile phase, Standard preparation, System suitability solution, and Chromatographic system—Prepare as directed in the Assay under Diphenhydramine Hydrochloride.
to: Mobile phase—Prepare a solution of acetonitrile, water,… Read More
Line 2: Change Mobile phase, Standard preparation, System suitability solution, and Chromatographic system—Prepare as directed in the Assay under Diphenhydramine Hydrochloride.
to: Mobile phase—Prepare a solution of acetonitrile, water, and triethylamine (50:
50: 0.5), adjust with glacial acetic acid to a pH of 6.5, filter, and degas. Make adjustments if necessary (see System Suitability under Chromatography <621>). Standard preparation—Dissolve an accurately weighed quantity of USP Diphenhydramine Hydrochloride RS in water to obtain a solution having a known concentration of about 0.5 mg per mL. AND After the Assay preparation subsection: Add System suitability solution—Dissolve about 5 mg of benzophenone in 5 mL of acetonitrile, dilute with water to 100 mL, and mix. Transfer 1.0 mL of this solution and 5 mg of diphenhydramine hydrochloride to a 10-mL volumetric flask, dilute with water to volume, and mix. Chromatographic system (see Chromatography <621>)—The liquid chromatograph is equipped with a 254-nm detector and a 4.6-mm × 25-cm column that contains packing L10. The flow rate is about 1 mL per minute. Chromatograph the System suitability solution, and record the peak responses as directed for Procedure; the resolution, R, between the benzophenone and diphenhydramine peaks is not less than 2.0. Chromatograph replicate injections of the Standard preparation, and record the peak responses as directed for Procedure; the relative standard deviation is not more than 2.0%, and the tailing factor for the diphenhydramine hydrochloride peak is not more than 2.0.
AND Line 1 of Procedure: Change Proceed as directed for Procedure in the Assay under Diphenhydramine Hydrochloride. to: Separately inject equal volumes, about 10 μL, of the Standard preparation and the Assay preparation into the chromatograph, record the chromatograms, and measure the responses for the major peaks.
|
EDETATE DISODIUM |
ASSAY/Procedure |
USP36–NF31
|
3370 |
26-Jul-2013 |
1-Aug-2013 |
USP38–NF33
|
First Supplement to USP37–NF32
|
Line 5: Delete Titrimetric system (See Titrimetry <541>.) Mode: Direct titration Titrant: 0.1 N sodium hydroxide VS Endpoint detection: Visual |
EDETATE DISODIUM |
ASSAY/Procedure |
USP36–NF31
|
3370 |
26-Jul-2013 |
1-Aug-2013 |
USP38–NF33
|
First Supplement to USP37–NF32
|
Line 16 of Analysis: Change Calculate the percentage of edetate disodium to: Calculate the weight of edetate disodium AND Line 19 of Analysis: Change Result = (VT/VU) ×
W ×
(Mr1/Mr2) ×… Read More
Line 16 of Analysis: Change Calculate the percentage of edetate disodium to: Calculate the weight of edetate disodium AND Line 19 of Analysis: Change Result = (VT/VU) ×
W ×
(Mr1/Mr2) × 100
to: Result = (VT/VU) ×
W ×
(Mr1/Mr2)
|
FELBAMATE TABLETS |
IMPURITIES/Organic Impurities/System suitability/Suitability requirements |
USP36–NF31
|
3537 |
26-Jul-2013 |
1-Aug-2013 |
USP38–NF33
|
First Supplement to USP37–NF32
|
Line 1 of Resolution: Change NMT 2 to: NLT 2 |
FEXOFENADINE HYDROCHLORIDE TABLETS |
ASSAY/Procedure |
USP36–NF31
|
3576 |
26-Jul-2013 |
1-Aug-2013 |
USP38–NF33
|
First Supplement to USP37–NF32
|
Line 6 of Sample stock solution: Change (equivalent to 80% of the total flask volume) to: (sufficient to fill the flask to 80% of its volume) |
FLUPHENAZINE DECANOATE INJECTION |
Assay |
USP36–NF31
|
3639 |
26-Jul-2013 |
1-Aug-2013 |
USP38–NF33
|
First Supplement to USP37–NF32
|
Line 11 of Standard preparation: Delete (1:5)
AND Line 8 of Assay preparation: Delete (1:5) |
LAMOTRIGINE TABLETS |
PERFORMANCE TESTS/Dissolution <711>/Test 1 |
USP36–NF31
|
4056 |
26-Jul-2013 |
1-Aug-2013 |
USP38–NF33
|
First Supplement to USP37–NF32
|
Line 3 of Standard solution: Change 0.028 µg/mL to: 0.028 mg/mL |
LEVOFLOXACIN |
ADDITIONAL REQUIREMENTS/USP Reference Standards <11> |
USP36–NF31
|
4099 |
26-Jul-2013 |
1-Aug-2013 |
USP38–NF33
|
First Supplement to USP37–NF32
|
Line 2 of USP Levofloxacin Related Compound A RS: Change
(S)-9-Fluoro-3-methyl-10-(piperazin-1-yl)-7-oxo-2,3-dihydro-7H-pyrido[1,2,3-de][1,4-benzoxazine-6-carbocylic acid. to: (S)-9-Fluoro-3-methyl-10-(piperazin-1-yl)-7-oxo-2,3-dihydro-7H-pyrido[1,2,3-… Read More
Line 2 of USP Levofloxacin Related Compound A RS: Change
(S)-9-Fluoro-3-methyl-10-(piperazin-1-yl)-7-oxo-2,3-dihydro-7H-pyrido[1,2,3-de][1,4-benzoxazine-6-carbocylic acid. to: (S)-9-Fluoro-3-methyl-10-(piperazin-1-yl)-7-oxo-2,3-dihydro-7H-pyrido[1,2,3-de][1,4]benzoxazine-6-carboxylic acid.
AND
Line 2 of USP Levofloxacin Related Compound B RS: Change
(S)-9,10-Difluoro-3-methyl-7-oxo-2,3-dihydro-7H-pyrido[1,2,3-de][1,4-benzoxazine-6-carbocylic acid. to: (S)-9,10-Difluoro-3-methyl-7-oxo-2,3-dihydro-7H-pyrido[1,2,3-de][1,4]benzoxazine-6-carboxylic acid.
|
MOXIFLOXACIN OPHTHALMIC SOLUTION |
Related compounds |
USP36–NF31
|
4414 |
26-Jul-2013 |
1-Aug-2013 |
USP38–NF33
|
First Supplement to USP37–NF32
|
Row 1 of Column 3 of Table 2: Change Relative Retention Time vs. Moxifloxacin to: Relative Retention vs. Moxifloxacin AND Row 1 of Column 3 of Table 3: Change Relative Retention Time vs. Moxifloxacin to: Relative Retention vs. Moxifloxacin |
NIFEDIPINE EXTENDED-RELEASE TABLETS |
PERFORMANCE TESTS/Dissolution <711>/Test 4/Instrumental conditions |
USP36–NF31
|
4509 |
26-Jul-2013 |
1-Aug-2013 |
USP38–NF33
|
First Supplement to USP37–NF32
|
Line 1 of Cell: Change 0.5 cm to: 1 cm |
OLMESARTAN MEDOXOMIL |
IMPURITIES/Organic Impurities/Impurity Table |
USP36–NF31
|
4570 |
26-Jul-2013 |
1-Aug-2013 |
USP38–NF33
|
First Supplement to USP37–NF32
|
Footnote d: Change ((5-Methyl-2-oxo-1,3-dioxol-4-yl)methyl 4-(2-hydroxypropan-2-yl)-2-propyl-1-((2´-(1-trityl-1H-tetrazol-5-yl)biphenyl-4-yl)methyl)-1H-imidazole-5-carboxylate. to: (5-Methyl-2-oxo-1,3-dioxol-4-yl)methyl 4-(2-hydroxypropan-2-yl)-2-propyl-1-((2´-(2-trityl-1… Read More
Footnote d: Change ((5-Methyl-2-oxo-1,3-dioxol-4-yl)methyl 4-(2-hydroxypropan-2-yl)-2-propyl-1-((2´-(1-trityl-1H-tetrazol-5-yl)biphenyl-4-yl)methyl)-1H-imidazole-5-carboxylate. to: (5-Methyl-2-oxo-1,3-dioxol-4-yl)methyl 4-(2-hydroxypropan-2-yl)-2-propyl-1-((2´-(2-trityl-1H-tetrazol-5-yl)biphenyl-4-yl)methyl)-1H-imidazole-5-carboxylate.
|
TRAMADOL HYDROCHLORIDE EXTENDED-RELEASE TABLETS |
IMPURITIES/Organic Impurities/Table 2 |
USP36–NF31
|
5438 |
26-Jul-2013 |
1-Aug-2013 |
USP38–NF33
|
First Supplement to USP37–NF32
|
Footnote c: Change 1-(3-Methoxyphenyl)-2-(dimethylaminomethyl) cyclohex-1-ene hydrochloride (identified and reported as an individual unspecified impurity if present). to: 1-(3-Methoxyphenyl)-2-(dimethylaminomethyl) cyclohex-6-ene hydrochloride (identified and reported as an individual… Read More
Footnote c: Change 1-(3-Methoxyphenyl)-2-(dimethylaminomethyl) cyclohex-1-ene hydrochloride (identified and reported as an individual unspecified impurity if present). to: 1-(3-Methoxyphenyl)-2-(dimethylaminomethyl) cyclohex-6-ene hydrochloride (identified and reported as an individual unspecified impurity if present). AND Footnote d: Change 1-(3-Methoxyphenyl)-2-(dimethylaminomethyl) cyclohex-6-ene hydrochloride (identified and reported as an individual unspecified impurity if present). to: 1-(3-Methoxyphenyl)-2-(dimethylaminomethyl) cyclohex-1-ene hydrochloride (identified and reported as an individual unspecified impurity if present).
|
VENLAFAXINE HYDROCHLORIDE |
ADDITIONAL REQUIREMENTS/USP Reference Standards <11> |
USP36–NF31
|
5551 |
26-Jul-2013 |
1-Aug-2013 |
USP38–NF33
|
First Supplement to USP37–NF32
|
Line 2 of Venlafaxine Related Compound A RS: Change 1-(1-(4-methoxyphenyl)-2-(methylamino)ethyl)cyclohexanol.
C16H25NO2 263.38 to: 1-(1-(4-Methoxyphenyl)-2-(methylamino)ethyl)cyclohexanol hydrochloride. C16H25NO2… Read More
Line 2 of Venlafaxine Related Compound A RS: Change 1-(1-(4-methoxyphenyl)-2-(methylamino)ethyl)cyclohexanol.
C16H25NO2 263.38 to: 1-(1-(4-Methoxyphenyl)-2-(methylamino)ethyl)cyclohexanol hydrochloride. C16H25NO2 · HCl 299.84
|
VENLAFAXINE TABLETS |
ADDITIONAL REQUIREMENTS/USP Reference Standards <11> |
USP36–NF31
|
5554 |
26-Jul-2013 |
1-Aug-2013 |
USP38–NF33
|
First Supplement to USP37–NF32
|
Line 2 of Venlafaxine Related Compound A RS: Change 1-(1-(4-methoxyphenyl)-2-(methylamino)ethyl)cyclohexanol. C16H25NO2 263.38 to: 1-(1-(4-Methoxyphenyl)-2-(methylamino)ethyl)cyclohexanol hydrochloride. C16H25NO2… Read More
Line 2 of Venlafaxine Related Compound A RS: Change 1-(1-(4-methoxyphenyl)-2-(methylamino)ethyl)cyclohexanol. C16H25NO2 263.38 to: 1-(1-(4-Methoxyphenyl)-2-(methylamino)ethyl)cyclohexanol hydrochloride. C16H25NO2 · HCl 299.84
|
GYMNEMA |
IDENTIFICATION/B. Thin-Layer Chromatography/Chromatographic system |
First Supplement to USP36–NF31
|
5880 |
26-Jul-2013 |
1-Aug-2013 |
USP38–NF33
|
First Supplement to USP37–NF32
|
Line 2 of Adsorbent: Change 5m to: 5 µm |
POWDERED GYMNEMA |
IDENTIFICATION/B. Thin-Layer Chromatography/Chromatographic system |
First Supplement to USP36–NF31
|
5883 |
26-Jul-2013 |
1-Aug-2013 |
USP38–NF33
|
First Supplement to USP37–NF32
|
Line 2 of Adsorbent: Change 5m to: 5 µm |
PURIFIED GYMNEMA EXTRACT |
COMPOSITION/Content of Gymnemic Acids |
First Supplement to USP36–NF31
|
5884 |
26-Jul-2013 |
1-Aug-2013 |
USP38–NF33
|
First Supplement to USP37–NF32
|
Line 1 of Acceptance criteria: Change 90%–110% of the labeled amount
to: 90.0%–110.0% of the labeled amount on the dried basis |
GENTAMICIN SULFATE |
IMPURITIES/Limit of Methanol |
First Supplement to USP36–NF31
|
5990 |
26-Jul-2013 |
1-Aug-2013 |
USP38–NF33
|
First Supplement to USP37–NF32
|
Line 11 of Analysis:
Change Result = (RU/RS) × (CS/CU) × D × F × 100 to: Result = (RU/RS) × (CS… Read More
Line 11 of Analysis:
Change Result = (RU/RS) × (CS/CU) × D × F × 100 to: Result = (RU/RS) × (CS/CU) × D × F AND Line 18 of Analysis: Change CS = percentage of methanol in the Standard solution (% v/v) to: CS = percentage of methanol in the Standard solution AND Line 23 of Analysis: Change F = conversion factor, 0.001 g/mg to: F = conversion factor, 1000 mg/g
|
MEPROBAMATE TABLETS |
ASSAY/Procedure |
First Supplement to USP36–NF31
|
6015 |
26-Jul-2013 |
1-Aug-2013 |
USP38–NF33
|
First Supplement to USP37–NF32
|
Line 4 of Standard solution: Change Dissolve in 30% of the final flask volume, and dilute with water to volume.
to: Dissolve in 30% of the final flask volume of acetonitrile, and dilute with water to volume. |
OXCARBAZEPINE |
IMPURITIES/Organic Impurities, Procedure 1 |
First Supplement to USP36–NF31
|
6035 |
26-Jul-2013 |
1-Aug-2013 |
USP38–NF33
|
First Supplement to USP37–NF32
|
Row 4 of Column 1 of Table 1: Change Dibenzazepinoneb to: Oxcarbazepine related compound E AND Delete footnote b AND Reletter the following footnotes in both the table and footnote definitions: c to b d to c e to d |
OXCARBAZEPINE |
IMPURITIES/Organic Impurities, Procedure 2 |
First Supplement to USP36–NF31
|
6035 |
26-Jul-2013 |
1-Aug-2013 |
USP38–NF33
|
First Supplement to USP37–NF32
|
Row 9 of Column 1 of Table 3: Change Oxcarbazepine related compound Eg to: Oxcarbazepine related compound E AND Delete footnote g |
ISOTRETINOIN CAPSULES |
PERFORMANCE TESTS/Dissolution <711>/Test 4 |
Revision Bulletin (Official October 01, 2012)
|
Online |
31-May-2013 |
1-Jun-2013 |
USP37–NF32
|
USP37–NF32
|
Line 2 of Medium: Change 4.5% (v/v) of Milloxid L (lauryl dimethyl amine oxide) to: 4.5% (v/v) of lauryl dimethyl amine oxide |
<228> ETHYLENE OXIDE AND DIOXANE |
Method II |
USP36–NF31
|
148 |
31-May-2013 |
1-Jun-2013 |
USP37–NF32
|
USP37–NF32
|
Line 31 of Analysis: Change rS = ethylene oxide peak responses from Standard solution B to:
rS = dioxane peak responses from Standard solution B |
<1052> BIOTECHNOLOGY-DERIVED ARTICLES—AMINO ACID ANALYSIS |
METHODOLOGIES OF AMINO ACID ANALYSIS GENERAL PRINCIPLES |
USP36–NF31
|
619 |
31-May-2013 |
1-Jun-2013 |
USP37–NF32
|
USP37–NF32
|
Change the section title Method 6—Postcolumn DABS-CI Derivatization General Principle to: Method 6—Precolumn DABS-CI Derivatization General Principle |
<1052> BIOTECHNOLOGY-DERIVED ARTICLES—AMINO ACID ANALYSIS |
APPENDIX |
USP36–NF31
|
619 |
31-May-2013 |
1-Jun-2013 |
USP37–NF32
|
USP37–NF32
|
Change the section title Method 6—Postcolumn DABS-CI Derivatization to: Method 6—Precolumn DABS-CI Derivatization |
CARAWAY OIL |
DEFINITION |
USP36–NF31
|
1924 |
31-May-2013 |
1-Jun-2013 |
USP37–NF32
|
USP37–NF32
|
Line 3: Change It contains NMT 50.0% of d-carvone (C10H14O). to: It contains NLT 50.0% of d-carvone (C10H14O). |
NITRIC ACID |
ASSAY/Procedure |
USP36–NF31
|
2107 |
31-May-2013 |
1-Jun-2013 |
USP37–NF32
|
USP37–NF32
|
Line 1 of Sample solution: Change To 2 mL of Nitric Acid in a tared, glass-stoppered conical flask add 25 mL of water. to: Weigh 2 mL of Nitric Acid in a glass-stoppered conical flask, and add 25 mL of water. |
ALBUTEROL SULFATE |
Chromatographic purity |
USP36–NF31
|
2352 |
31-May-2013 |
1-Jun-2013 |
USP37–NF32
|
USP37–NF32
|
Line 1: Change It meets the requirements of the test for Chromatographic purity under Albuterol, except to read Albuterol Sulfate in place of Albuterol and to use water instead of methanol as the solvent to prepare the Standard solution and the Test solution.
to… Read More
Line 1: Change It meets the requirements of the test for Chromatographic purity under Albuterol, except to read Albuterol Sulfate in place of Albuterol and to use water instead of methanol as the solvent to prepare the Standard solution and the Test solution.
to: It meets the requirements of the test for Organic Impurities under Albuterol, except to read Albuterol Sulfate in place of Albuterol and to use water instead of methanol as the solvent to prepare the Standard solution and the Sample solution.
|
AMITRIPTYLINE HYDROCHLORIDE TABLETS |
IDENTIFICATION/A. |
USP36–NF31
|
2464 |
31-May-2013 |
1-Jun-2013 |
USP37–NF32
|
USP37–NF32
|
Line 2: Change Sample solution: Nominally 0.01 mg/mL of amitriptyline hydrochloride in methanol from a suitable amount of finely powdered Tablets. Filter a portion of the solution, and use the filtrate for analysis. to: Sample stock solution: Nominally 0.1 mg/mL of… Read More
Line 2: Change Sample solution: Nominally 0.01 mg/mL of amitriptyline hydrochloride in methanol from a suitable amount of finely powdered Tablets. Filter a portion of the solution, and use the filtrate for analysis. to: Sample stock solution: Nominally 0.1 mg/mL of amitriptyline hydrochloride in methanol from a suitable amount of finely powdered Tablets. Filter a portion of the solution, and use the filtrate. Sample solution: Nominally 0.01 mg/mL of amitriptyline hydrochloride from Sample stock solution in methanol
|
FOSPHENYTOIN SODIUM |
USP Reference standards <11> |
USP36–NF31
|
3679 |
31-May-2013 |
1-Jun-2013 |
USP37–NF32
|
USP37–NF32
|
Line 6: Change C14H15NO2 to: C14H13NO2 |
FOSPHENYTOIN SODIUM INJECTION |
USP Reference standards <11> |
USP36–NF31
|
3680 |
31-May-2013 |
1-Jun-2013 |
USP37–NF32
|
USP37–NF32
|
Line 6: Change C14H15NO2 to: C14H13NO2 |
FOSPHENYTOIN SODIUM INJECTION |
Assay |
USP36–NF31
|
3680 |
31-May-2013 |
1-Jun-2013 |
USP37–NF32
|
USP37–NF32
|
Line 1 of Assay preparation: Change Transfer an accurately measured volume of the Injection, equivalent to about 300 mg of fosphenytoin, to: Transfer an accurately measured volume of the Injection, equivalent to about 300 mg of fosphenytoin sodium, |
MINOCYCLINE HYDROCHLORIDE CAPSULES |
Assay |
USP36–NF31
|
4375 |
31-May-2013 |
1-Jun-2013 |
USP37–NF32
|
USP37–NF32
|
Line 2: Change Mobile phase, Standard preparation, Resolution solution, and Chromatographic system—Proceed as directed in the Assay under Minocycline Hydrochloride. to: Mobile phase—Prepare a mixture of 0.2 M ammonium oxalate, 0.01 M edetate… Read More
Line 2: Change Mobile phase, Standard preparation, Resolution solution, and Chromatographic system—Proceed as directed in the Assay under Minocycline Hydrochloride. to: Mobile phase—Prepare a mixture of 0.2 M ammonium oxalate, 0.01 M edetate disodium, dimethylformamide, and tetrahydrofuran (600:180:120:80). Adjust with ammonium hydroxide to a pH of 7.2, and pass through a filter of 0.5-µm or finer pore size. Make adjustments if necessary (see System Suitability under Chromatography <621>). Standard preparation—Dissolve an accurately weighed quantity of USP Minocycline Hydrochloride RS in water to obtain a solution having a known concentration of about 500 µg of minocycline (C23H27N3O7) per mL. Use this solution within 3 hours. Resolution solution—Transfer 10 mg of USP Minocycline Hydrochloride RS to a 25-mL volumetric flask, add 20 mL of 0.2 M ammonium oxalate, and swirl to dissolve. Heat on a water bath at 60° for 180 minutes, and allow to cool. Dilute with water to volume, and mix. Chromatographic system (see Chromatography <621>)—The liquid chromatograph is equipped with a 280-nm detector and a 4.6-mm × 25-cm column that contains 5-µm packing L1, and is maintained at a constant temperature of about 40°. The flow rate is about 1.5 mL per minute. Chromatograph the Standard preparation, and record the peak responses as directed for Procedure: the capacity factor, k´, is not less than 5.0 and not more than 11.5; the tailing factor for the analyte peak is not less than 0.9 and not more than 2.0; and the relative standard deviation for replicate injections is not more than 2.0%. Chromatograph the Resolution solution, and record the peak responses as directed for Procedure: the relative retention times are about 0.7 for epiminocycline and 1.0 for minocycline; and the resolution, R, between epiminocycline and minocycline is not less than 4.6. AND Line 1 of Procedure: Change Proceed as directed for Procedure in the Assay under Minocycline Hydrochloride. to: Separately inject equal volumes (about 20 µL) of the Standard preparation and the Assay preparation into the chromatograph, record the chromatograms, and measure the responses for the major peaks.
|
MINOCYCLINE FOR INJECTION |
Assay |
USP36–NF31
|
4375 |
31-May-2013 |
1-Jun-2013 |
USP37–NF32
|
USP37–NF32
|
Line 2: Change Mobile phase, Standard preparation, Resolution solution, and Chromatographic system—Proceed as directed in the Assay under Minocycline Hydrochloride. to: Mobile phase—Prepare a mixture of 0.2 M ammonium oxalate, 0.01 M edetate… Read More
Line 2: Change Mobile phase, Standard preparation, Resolution solution, and Chromatographic system—Proceed as directed in the Assay under Minocycline Hydrochloride. to: Mobile phase—Prepare a mixture of 0.2 M ammonium oxalate, 0.01 M edetate disodium, dimethylformamide, and tetrahydrofuran (600:180:120:80). Adjust with ammonium hydroxide to a pH of 7.2, and pass through a filter of 0.5-µm or finer porosity. Make adjustments if necessary (see System Suitability under Chromatography <621>). Standard preparation—Dissolve an accurately weighed quantity of USP Minocycline Hydrochloride RS in water to obtain a solution having a known concentration of about 500 µg of minocycline (C23H27N3O7) per mL. Use this solution within 3 hours. Resolution solution—Transfer 10 mg of USP Minocycline Hydrochloride RS to a 25-mL volumetric flask, add 20 mL of 0.2 M ammonium oxalate, and swirl to dissolve. Heat on a water bath at 60° for 180 minutes, and allow to cool. Dilute with water to volume, and mix. Chromatographic system (see Chromatography <621>)—The liquid chromatograph is equipped with a 280-nm detector and a 4.6-mm × 25-cm column that contains 5-µm packing L1, and is maintained at a constant temperature of about 40°. The flow rate is about 1.5 mL per minute. Chromatograph the Standard preparation, and record the peak responses as directed for Procedure: the capacity factor, k´, is not less than 5.0 and not more than 11.5; the tailing factor for the analyte peak is not less than 0.9 and not more than 2.0; and the relative standard deviation for replicate injections is not more than 2.0%. Chromatograph the Resolution solution, and record the peak responses as directed for Procedure: the relative retention times are about 0.7 for epiminocycline and 1.0 for minocycline; and the resolution, R, between epiminocycline and minocycline is not less than 4.6. AND Line 1 of Procedure: Change Proceed as directed for Procedure in the Assay under Minocycline Hydrochloride. to: Separately inject equal volumes (about 20 µL) of the Standard preparation and the Assay preparation into the chromatograph, record the chromatograms, and measure the responses for the major peaks.
|
MINOCYCLINE HYDROCHLORIDE ORAL SUSPENSION |
Assay |
USP36–NF31
|
4376 |
31-May-2013 |
1-Jun-2013 |
USP37–NF32
|
USP37–NF32
|
Line 2: Change Mobile phase and Chromatographic system—Proceed as directed in the Assay under Minocycline Hydrochloride. to: Mobile phase—Prepare a mixture of 0.2 M ammonium oxalate, 0.01 M edetate disodium, dimethylformamide, and tetrahydrofuran (600:180… Read More
Line 2: Change Mobile phase and Chromatographic system—Proceed as directed in the Assay under Minocycline Hydrochloride. to: Mobile phase—Prepare a mixture of 0.2 M ammonium oxalate, 0.01 M edetate disodium, dimethylformamide, and tetrahydrofuran (600:180:120:80). Adjust with ammonium hydroxide to a pH of 7.2, and pass through a filter of 0.5-µm or finer pore size. Make adjustments if necessary (see System Suitability under Chromatography <621>). Chromatographic system (see Chromatography <621>)—The liquid chromatograph is equipped with a 280-nm detector and a 4.6-mm × 25-cm column that contains 5-µm packing L1, and is maintained at a constant temperature of about 40°. The flow rate is about 1.5 mL per minute. Chromatograph the Standard preparation, and record the peak responses as directed for Procedure: the capacity factor, k´, is not less than 5.0 and not more than 11.5; the tailing factor for the analyte peak is not less than 0.9 and not more than 2.0; and the relative standard deviation for replicate injections is not more than 2.0%. Chromatograph the Resolution solution, and record the peak responses as directed for Procedure: the relative retention times are about 0.7 for epiminocycline and 1.0 for minocycline; and the resolution, R, between epiminocycline and minocycline is not less than 4.6. AND Line 1 of Procedure: Change Proceed as directed for Procedure in the Assay under Minocycline Hydrochloride. to: Separately inject equal volumes (about 20 µL) of the Standard preparation and the Assay preparation into the chromatograph, record the chromatograms, and measure the responses for the major peaks.
|
MINOCYCLINE HYDROCHLORIDE TABLETS |
Assay |
USP36–NF31
|
4378 |
31-May-2013 |
1-Jun-2013 |
USP37–NF32
|
USP37–NF32
|
Line 2: Change Mobile phase, Standard preparation, Resolution solution, and Chromatographic system—Proceed as directed in the Assay under Minocycline Hydrochloride. to: Mobile phase—Prepare a mixture of 0.2 M ammonium oxalate, 0.01 M… Read More
Line 2: Change Mobile phase, Standard preparation, Resolution solution, and Chromatographic system—Proceed as directed in the Assay under Minocycline Hydrochloride. to: Mobile phase—Prepare a mixture of 0.2 M ammonium oxalate, 0.01 M edetate disodium, dimethylformamide, and tetrahydrofuran (600:180:120:80). Adjust with ammonium hydroxide to a pH of 7.2, and pass through a filter of 0.5-µm or finer pore size. Make adjustments if necessary (see System Suitability under Chromatography <621>). Standard preparation—Dissolve an accurately weighed quantity of USP Minocycline Hydrochloride RS in water to obtain a solution having a known concentration of about 500 µg of minocycline (C23H27N3O7) per mL. Use this solution within 3 hours. Resolution solution—Transfer 10 mg of USP Minocycline Hydrochloride RS to a 25-mL volumetric flask, add 20 mL of 0.2 M ammonium oxalate, and swirl to dissolve. Heat on a water bath at 60° for 180 minutes, and allow to cool. Dilute with water to volume, and mix. Chromatographic system (see Chromatography <621>)—The liquid chromatograph is equipped with a 280-nm detector and a 4.6-mm × 25-cm column that contains 5-µm packing L1, and is maintained at a constant temperature of about 40°. The flow rate is about 1.5 mL per minute. Chromatograph the Standard preparation, and record the peak responses as directed for Procedure: the capacity factor, k´, is not less than 5.0 and not more than 11.5; the tailing factor for the analyte peak is not less than 0.9 and not more than 2.0; and the relative standard deviation for replicate injections is not more than 2.0%. Chromatograph the Resolution solution, and record the peak responses as directed for Procedure: the relative retention times are about 0.7 for epiminocycline and 1.0 for minocycline; and the resolution, R, between epiminocycline and minocycline is not less than 4.6. AND Line 1 of Procedure: Change Proceed as directed for Procedure in the Assay under Minocycline Hydrochloride. to: Separately inject equal volumes (about 20 µL) of the Standard preparation and the Assay preparation into the chromatograph, record the chromatograms, and measure the responses for the major peaks.
|
MOXIFLOXACIN OPHTHALMIC SOLUTION |
Assay |
USP36–NF31
|
4414 |
31-May-2013 |
1-Jun-2013 |
USP37–NF32
|
USP37–NF32
|
Line 4 of Resolution solution: Change 0.1 mg per mg and 0.001 mg per mg, to: 0.1 mg per mL and 0.001 mg per mL, |
NIFEDIPINE EXTENDED-RELEASE TABLETS |
PERFORMANCE TESTS/Dissolution <711>/Test 2 |
USP36–NF31
|
4509 |
31-May-2013 |
1-Jun-2013 |
USP37–NF32
|
USP37–NF32
|
Line 1 of Solution A: Change Dissolve 330.9 mg of sodium phosphate to: Dissolve 330.9 g of dibasic sodium phosphate |
OXYCODONE AND ACETAMINOPHEN TABLETS |
IDENTIFICATION/A. Thin-Layer Chromatography |
USP36–NF31
|
4645 |
31-May-2013 |
1-Jun-2013 |
USP37–NF32
|
USP37–NF32
|
Line 2 of Sample solution: Change in a mixture of methanol and water (4:1). to: in a 5-mL mixture of methanol and water (4:1). |
OXYCODONE TEREPHTHALATE |
ASSAY/Procedure |
USP36–NF31
|
4648 |
31-May-2013 |
1-Jun-2013 |
USP37–NF32
|
USP37–NF32
|
Line 7 of Analysis: Change RU = internal standard ratio (peak response of oxycodone/peak response of ethylparaben) from the Standard solution RS = internal standard ratio (peak response of oxycodone/peak response of ethylparaben) from the … Read More
Line 7 of Analysis: Change RU = internal standard ratio (peak response of oxycodone/peak response of ethylparaben) from the Standard solution RS = internal standard ratio (peak response of oxycodone/peak response of ethylparaben) from the Sample solution to: RU = peak response ratio of oxycodone to ethylparaben from the Sample solution RS = peak response ratio of oxycodone to ethylparaben from the Standard solution
|
PENTAZOCINE INJECTION |
Chemical Information |
USP36–NF31
|
4734 |
31-May-2013 |
1-Jun-2013 |
USP37–NF32
|
USP37–NF32
|
Line 1: Remove all chemical information. |
POTASSIUM BICARBONATE EFFERVESCENT TABLETS FOR ORAL SOLUTION |
Assay |
USP36–NF31
|
4833 |
31-May-2013 |
1-Jun-2013 |
USP37–NF32
|
USP37–NF32
|
Line 2: Change Potassium stock solution
and Standard preparations— to: Standard stock solution
and Standard solutions— AND Line 1 of Procedure: Change for Procedure in the Assay under Potassium Chloride Oral Solution. to… Read More
Line 2: Change Potassium stock solution
and Standard preparations— to: Standard stock solution
and Standard solutions— AND Line 1 of Procedure: Change for Procedure in the Assay under Potassium Chloride Oral Solution. to: for Instrumental conditions and Analysis in the Assay under Potassium Chloride Oral Solution, except use Assay preparation instead of Sample solution.
|
POTASSIUM BICARBONATE AND POTASSIUM CHLORIDE FOR EFFERVESCENT ORAL SOLUTION |
Assay for potassium |
USP36–NF31
|
4834 |
31-May-2013 |
1-Jun-2013 |
USP37–NF32
|
USP37–NF32
|
Line 2: Change Potassium stock solution
and Standard preparations— to: Standard stock solution
and Standard solutions— AND Line 1 of Procedure: Change for Procedure in the Assay under Potassium Chloride Oral Solution. to… Read More
Line 2: Change Potassium stock solution
and Standard preparations— to: Standard stock solution
and Standard solutions— AND Line 1 of Procedure: Change for Procedure in the Assay under Potassium Chloride Oral Solution. to: for Instrumental conditions and Analysis in the Assay under Potassium Chloride Oral Solution, except use Assay preparation instead of Sample solution.
|
POTASSIUM BICARBONATE AND POTASSIUM CHLORIDE EFFERVESCENT TABLETS FOR ORAL SOLUTION |
Assay for potassium |
USP36–NF31
|
4834 |
31-May-2013 |
1-Jun-2013 |
USP37–NF32
|
USP37–NF32
|
Line 2: Change Potassium stock solution
and Standard preparations— to: Standard stock solution
and Standard solutions— AND Line 1 of Procedure: Change for Procedure in the Assay under Potassium Chloride Oral Solution. to… Read More
Line 2: Change Potassium stock solution
and Standard preparations— to: Standard stock solution
and Standard solutions— AND Line 1 of Procedure: Change for Procedure in the Assay under Potassium Chloride Oral Solution. to: for Instrumental conditions and Analysis in the Assay under Potassium Chloride Oral Solution, except use Assay preparation instead of Sample solution.
|